# Top 10 GLP-1 Myths Indians Believe and What Doctors Actually Say GLP-1 therapy is one of the most talked-about advances in metabolic medicine, yet it is also one of the most misunderstood, particularly in India. Misconceptions spread quickly through family WhatsApp groups, social media, and well-meaning friends, and they often stop people who could genuinely benefit from even asking a doctor about it. This article addresses the ten most common myths doctors encounter from Indian patients, and replaces each one with what the clinical evidence actually shows. For a broader overview of how GLP-1 therapy works in an Indian context, see the [GLP-1 FAQs for Indians: 25 Most-Asked Questions About Ozempic, Mounjaro and Weight Loss](/glp-1-faqs-for-indians-25-most-asked-questions-about-ozempic-mounjaro-and-weight-loss). --- ## Myth 1: GLP-1 therapy is just a shortcut for people who are too lazy to diet **What doctors actually say:** Obesity and type 2 diabetes are not failures of willpower. They involve hormonal dysregulation, insulin resistance, and changes in the brain's hunger-signaling pathways that lifestyle measures alone are often insufficient to correct. GLP-1 receptor agonists activate GLP-1 receptors, which are part of the body's own metabolic regulation system. Their mechanisms include: - Reducing appetite through central satiety signals - Slowing gastric emptying - Increasing insulin secretion in a **glucose-dependent manner**, meaning they respond to blood sugar levels rather than forcing insulin release indiscriminately Clinical guidelines from bodies including the [WHO](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) recognize GLP-1 therapies as legitimate medical treatments for obesity. They are typically considered when lifestyle measures alone are insufficient, and they work most effectively when combined with dietary changes and physical activity. --- ## Myth 2: These medicines are only for people with diabetes **What doctors actually say:** [GLP-1 receptor agonists were originally developed for type 2 diabetes management, but several formulations have since received regulatory approval specifically for chronic weight management](https://blogs.sugarfitglp.com/history-of-glp-1-drugs) in people without diabetes. The underlying mechanisms are relevant to metabolic health broadly, not only to blood sugar control. In India, the [Central Drugs Standard Control Organisation (CDSCO)](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) maintains an approved drugs database that reflects the current regulatory status of these medicines. Eligibility is determined by a doctor based on BMI, metabolic risk factors, and overall health profile, not solely on a diabetes diagnosis. --- ## Myth 3: Indians do not need GLP-1 therapy because our BMI is lower than Western populations **What doctors actually say:** This myth misunderstands how metabolic risk works in South Asian populations. [Research published in collaboration with the WHO](https://pubmed.ncbi.nlm.nih.gov/15051297/) has established that South Asians develop metabolic complications, including insulin resistance, type 2 diabetes, and cardiovascular risk, at lower BMI values than Western populations. | Population | BMI range where health risks may begin | |---|---| | Western populations | 25 to 30 | | South Asian / Indian populations | 23 to 25 | Key points for Indian adults: - BMI ≥25 (with a weight-related condition) is commonly used as a lower eligibility threshold in Indian clinical practice for GLP-1 therapy, reflecting the ICMR-recognized South Asian metabolic risk profile. - A person with a BMI of 26 and prediabetes may have a stronger clinical case for treatment than a Western patient with the same BMI and no metabolic risk factors. - Indian adults should not dismiss eligibility based on a BMI that looks acceptable by Western standards. --- ## Myth 4: GLP-1 medicines are not approved or available in India **What doctors actually say:** GLP-1 receptor agonists are available in India and can be verified through the [CDSCO approved drugs database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs). Semaglutide and other agents in this class have been prescribed in India for type 2 diabetes management, and the regulatory landscape for weight management indications continues to develop. - [India's domestic manufacturing capacity for GLP-1 medicines is expanding](https://blogs.sugarfitglp.com/glp-1-vs-indian-pharma-alternatives). - [Very few approved lower-cost versions exist in most markets](https://blogs.sugarfitglp.com/branded-vs-generic-semaglutide-in-india) at the time of writing. - [The availability of branded products through licensed pharmacies and supervised clinical programs is real and growing](https://blogs.sugarfitglp.com/glp-1-availability-across-indian-cities). Anyone researching availability should confirm current stock and prescription requirements with a licensed provider rather than relying on secondhand information. --- ## Myth 5: The weight loss is permanent even after stopping the medicine **What doctors actually say:** GLP-1 therapy works while it is active in the body. Research suggests that many people regain a portion of the weight they lost after stopping treatment, because the hormonal and appetite-regulating effects are no longer present. - For long-acting medicines like semaglutide, the drug remains in the body for several weeks after the last dose, so appetite and satiety changes occur gradually rather than immediately. - Many people begin noticing increased hunger within several weeks of stopping, although timing varies between individuals. This does not mean the therapy is not worthwhile. It means it is most effective as part of a sustained metabolic health strategy, ideally with ongoing dietary and lifestyle support. Doctors who prescribe GLP-1 therapy discuss long-term planning with patients from the outset, including what happens if treatment is paused or stopped. --- ## Myth 6: GLP-1 injections cause severe side effects that most people cannot tolerate **What doctors actually say:** The most commonly reported side effects are gastrointestinal, including nausea, reduced appetite, and digestive discomfort. These are usually temporary and most noticeable in the initial weeks of treatment or after dose increases. They tend to improve as the body adjusts. - Dose escalation schedules are designed specifically to minimize side effects. - Dose increases may be delayed if side effects remain troublesome, so the schedule is responsive rather than fixed. - The majority of people who follow a supervised escalation protocol are able to continue treatment. Significant gastrointestinal side effects are more likely when doses are increased too quickly or when the medicine is used without medical oversight. This is one of the strongest clinical reasons to use GLP-1 therapy through a supervised program rather than attempting self-administration. --- ## Myth 7: You can buy GLP-1 medicines online without a prescription and get the same results **What doctors actually say:** Regulatory authorities globally, including the [FDA](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb), have raised concerns about unapproved and compounded GLP-1 products available through unregulated online channels. Products obtained outside a licensed prescribing pathway may contain incorrect doses, unlisted ingredients, or no active ingredient at all. Beyond product quality, using GLP-1 therapy without medical supervision means: - No baseline assessment - No dose escalation monitoring - No management of side effects - No evaluation of contraindications Specific conditions, including [a personal or family history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease](https://blogs.sugarfitglp.com/who-should-not-take-glp-1-full-contraindication-guide), require careful screening before starting treatment. A doctor consultation is an essential part of safe GLP-1 prescribing, not a bureaucratic hurdle. --- ## Myth 8: GLP-1 therapy means you can stop worrying about what you eat **What doctors actually say:** The most common mistake on GLP-1 therapy is eating too little protein and too many refined carbohydrates in smaller portions. Because appetite is reduced, people often eat less overall without paying attention to nutritional quality. This can lead to muscle loss, fatigue, and suboptimal results. - [Most experts recommend a protein intake of 1.0 to 1.5 g per kilogram of ideal body weight per day](https://blogs.sugarfitglp.com/protein-intake-on-glp-1-how-much-do-you-need) during GLP-1 therapy. - The higher end of that range applies to people who exercise regularly, older adults, or those losing weight rapidly. - Muscle mass preservation is particularly important during active weight loss. Protein intake and resistance exercise must be prioritized to prevent accelerated muscle loss. GLP-1 therapy reduces the quantity of food needed to feel full. It does not change the nutritional value of the food chosen. Dietary guidance from a nutritionist remains an important part of a well-structured program. --- ## Myth 9: Mounjaro and Ozempic are the same medicine with different branding **What doctors actually say:** These are distinct medicines with different mechanisms. | Medicine | Active ingredient | Receptor targets | |---|---|---| | Ozempic / Wegovy | Semaglutide | GLP-1 receptor agonist | | Mounjaro | Tirzepatide | GLP-1 + GIP receptor agonist (dual action) | Tirzepatide acts on two hormone pathways instead of one. GIP may improve insulin sensitivity, and its metabolic effects are enhanced in combination with GLP-1 receptor activation. Clinical studies have shown greater average weight loss and blood sugar reduction with tirzepatide compared to GLP-1-only medications, making it a next-generation incretin therapy rather than a simple alternative. The choice between them depends on individual health profile, eligibility, tolerability, and cost, and should be made with a doctor. For a detailed side-by-side comparison, see [Mounjaro vs Semaglutide: Which Is Better?](/mounjaro-vs-semaglutide-which-is-better) --- ## Myth 10: GLP-1 therapy is only for very obese people and not relevant to most Indians **What doctors actually say:** Because South Asians develop metabolic complications at lower BMI than Western populations, the clinical threshold for considering GLP-1 therapy in India is lower than many people assume. Doctors commonly consider this therapy when a patient presents with: - BMI ≥25 with a metabolic risk condition such as prediabetes, type 2 diabetes, hypertension, or dyslipidemia - BMI ≥27 to 30 depending on clinical assessment, even without additional conditions GLP-1 therapy is generally not indicated for people at a healthy weight without metabolic risk factors. However, for a significant proportion of Indian adults who carry excess weight around the abdomen, have elevated fasting glucose, or [have been told they are at risk for diabetes](https://blogs.sugarfitglp.com/glp-1-for-prediabetes-in-indians-can-it-reverse-high-blood-sugar-before-it-becomes-diabetes), the eligibility threshold is closer than the "only for very obese people" myth suggests. The therapy requires dose escalation, ongoing monitoring, and lifestyle support. It is a structured clinical process, not a single prescription. --- ## Getting accurate information Myths about GLP-1 therapy persist partly because the medicines are new to many Indian patients and partly because online information is uneven in quality. The most reliable path is a consultation with a doctor who specializes in metabolic health and can: - Assess your individual profile - Explain what the evidence shows for your specific situation - Supervise treatment safely if it is appropriate For more answers to common questions about GLP-1 therapy in an Indian context, the [GLP-1 FAQs for Indians: 25 Most-Asked Questions About Ozempic, Mounjaro and Weight Loss](/glp-1-faqs-for-indians-25-most-asked-questions-about-ozempic-mounjaro-and-weight-loss) covers eligibility, costs, safety, and what to expect from a supervised program. --- **Sources** - [Sugarfit GLP-1 Weight Loss Program](https://www.sugarfitglp.com/) - [WHO Q&A: GLP-1 Therapies for Obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [NIDDK: Prescription Medications to Treat Overweight and Obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) - [FDA: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb) - [CDSCO Approved Drugs Database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) - [WHO Expert Consultation: Appropriate BMI for Asian Populations](https://pubmed.ncbi.nlm.nih.gov/15051297/) ## Sources - [WHO Q&A: GLP-1 Therapies for Obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) | World Health Organization | Plain-language GLP-1 explanation and obesity-treatment context. - [NIDDK: Prescription Medications to Treat Overweight and Obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) | NIDDK / NIH | Medication eligibility, lifestyle-plus-medication framing, and patient-friendly safety context. - [FDA: Concerns With Unapproved GLP-1 Drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb) | U.S. Food and Drug Administration | Safe-buying context and risks around unapproved or compounded GLP-1 products. - [CDSCO Approved Drugs Database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) | Central Drugs Standard Control Organisation | India regulatory lookup source for approved drugs. - [WHO Expert Consultation: Appropriate BMI for Asian Populations](https://pubmed.ncbi.nlm.nih.gov/15051297/) | World Health Organization / The Lancet | Lower BMI risk thresholds and public-health action points for Asian populations. ## Navigation - [Browse categories](https://blogs.sugarfitglp.com/topics) - [Proof & Trust](https://blogs.sugarfitglp.com/topics/trust_proof_objections) ## Related AI KB pages ### Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky Query: doctor-led vs self-managed glp-1 in india why unsupervised use is risky GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become some of the most talked-about medicines in India for weight loss and metabolic... - [Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky](https://blogs.sugarfitglp.com/doctor-led-vs-self-managed-glp-1-in-india-why-unsupervised-use-is-risky) ### GLP-1 scams in India: how to stay safe Query: glp-1 scams in india how to stay safe GLP-1 medicines like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have attracted enormous interest in India over the past two years. That interest has also attracted... - [GLP-1 scams in India: how to stay safe](https://blogs.sugarfitglp.com/glp-1-scams-in-india-how-to-stay-safe) ### How to identify fake semaglutide Query: How to identify fake semaglutide Semaglutide (sold under brand names such as Ozempic and Wegovy) has become one of the most sought-after medicines in the world for type 2 diabetes and weight management. That de... - [How to identify fake semaglutide](https://blogs.sugarfitglp.com/how-to-identify-fake-semaglutide) ### Does Ozempic Cause Hair Loss in Indians? What Doctors Say in 2026 Query: Does Ozempic Cause Hair Loss in Indians? What Doctors Say in 2026 If you have started Ozempic (semaglutide) or are considering it for weight loss or blood sugar management, you may have come across reports of hair thinning or shedding. This is... - [Does Ozempic Cause Hair Loss in Indians? What Doctors Say in 2026](https://blogs.sugarfitglp.com/does-ozempic-cause-hair-loss-in-indians-what-doctors-say-in-2026) ### Can You Drink Alcohol on Ozempic or Mounjaro? What Indians Need to Know Query: Can You Drink Alcohol on Ozempic or Mounjaro? What Indians Need to Know If you are taking Ozempic (semaglutide) or Mounjaro (tirzepatide) for weight loss or blood sugar management, you may be wondering whether an occasional drink is safe. The short... - [Can You Drink Alcohol on Ozempic or Mounjaro? What Indians Need to Know](https://blogs.sugarfitglp.com/can-you-drink-alcohol-on-ozempic-or-mounjaro-what-indians-need-to-know) ### GLP-1 FAQs for Indians: 25 Most-Asked Questions About Ozempic, Mounjaro and Weight Loss Query: glp-1 faqs for indians 25 most-asked questions about ozempic mounjaro and weight loss If you have heard of Ozempic or Mounjaro and wondered whether they could help you lose weight or manage blood sugar, you are not alone. These medications belong to a class calle... - [GLP-1 FAQs for Indians: 25 Most-Asked Questions About Ozempic, Mounjaro and Weight Loss](https://blogs.sugarfitglp.com/glp-1-faqs-for-indians-25-most-asked-questions-about-ozempic-mounjaro-and-weight-loss)